Gilead Sciences (GILD) Construction in Progress (2010 - 2025)

Gilead Sciences (GILD) posted Construction in Progress of $745.0 million for Q4 2025, up 48.7% quarter-over-quarter from $501.0 million in Q4 2024, and up 48.7% year-on-year from $501.0 million in Q4 2024.

Gilead Sciences (GILD) Construction in Progress (2010 - 2025) Analysis & Trends

Gilead Sciences (GILD) has reported Construction in Progress for 16 consecutive years, with $745.0 million the latest figure, recorded in Q4 2025.

  • Construction in Progress for Q4 2025 came in at $745.0 million, up 48.7% year-over-year; the trailing twelve-month figure through Dec 2025 was $745.0 million (up 48.7% YoY), and the FY2025 annual result was $745.0 million, up 48.7% from the prior year.
  • Construction in Progress was $745.0 million for Q4 2025 at Gilead Sciences, up from $501.0 million in the prior quarter.
  • Over five years, Construction in Progress peaked at $1.1 billion in Q4 2021 and troughed at $501.0 million in Q4 2024.
  • Average Construction in Progress over 5 years is $736.6 million, with a median of $719.0 million recorded in 2022.
  • Year-over-year, Construction in Progress sank 31.98% in 2022 and soared 48.7% in 2025.
  • Over 5 years, Construction in Progress stood at $1.1 billion in 2021, then tumbled by 31.98% to $719.0 million in 2022, then dropped by 8.07% to $661.0 million in 2023, then dropped by 24.21% to $501.0 million in 2024, then jumped by 48.7% to $745.0 million in 2025.
  • Per Business Quant data, the three most recent Construction in Progress figures were $745.0 million in Q4 2025, $501.0 million in Q4 2024, and $661.0 million in Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn -
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn -
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 745.00 Mn
Dec 31, 2024 501.00 Mn
Dec 31, 2023 661.00 Mn
Dec 31, 2022 719.00 Mn
Dec 31, 2021 1.06 Bn
Dec 31, 2020 856.00 Mn
Dec 31, 2019 723.00 Mn
Dec 31, 2018 1.19 Bn
Dec 31, 2017 690.00 Mn
Dec 31, 2016 641.00 Mn
Dec 31, 2015 554.00 Mn
Dec 31, 2014 411.00 Mn
Dec 31, 2013 129.00 Mn
Dec 31, 2012 216.43 Mn
Dec 31, 2011 60.75 Mn
Dec 31, 2010 82.33 Mn